Classifications: immunosuppressant; monoclonal antibody; interleukin-2 receptor antagonist; Therapeutic: immunosuppressant; monoclonal antibody
Pregnancy Category: B
20 mg vials
Immunosuppressant agent that is an interleukin-2 receptor monoclonal antibody produced by recombinant DNA technology. Binds
to and blocks interleukin-2R-alpha chain (CD-25 antibodies) on surface of activated T lymphocytes.
Binding to CD-25 antibodies inhibits a critical pathway in the immune response of the lymphocytes involved in allograft
Prophylaxis of acute renal transplant rejection.
Hypersensitivity to mannitol or murine protein; serious infection or exposure to viral infections (e.g., chickenpox, herpes
History of untoward reactions to dacliximab or other monoclonal antibodies; pregnancy (category B).
Route & Dosage
|Transplant Rejection Prophylaxis
Adult/Child (>35 kg): IV 20 mg times 2 doses (1st dose 2 h before surgery, 2nd dose 4 d after transplant)
Child (<35 kg, 215 y): IV 12 mg/m2 (max: 20 mg/dose) times 2 doses (1st dose 2 h before surgery, 2nd dose 4 d after transplant)
PREPARE: IV infusion: ??Add 2.5 mL or 5 mL sterile water for injection to the 10 mg or 20 mg vial, respectively. Rock vial gently to dissolve. May
be given as prepared direct IV as a bolus dose or further diluted in an infusion bag to a volume of 50 mL in NS or D5W. The
resulting solution has a concentration of 2.5 mg/mL.??Invert IV bag to dissolve but do not shake.??Discard if diluted solution is colored or has particulate matter. Use IV solution immediately.
ADMINISTER: Direct: Give bolus over 2030 sec. IV Infusion: Infuse the ordered dose of diluted drug over 2030 min.
- If necessary, the diluted solution may be stored at room temperature for 4 h or at 2°8° C (36°46°
F) for 24 h. Discard after 24 h.
- Store undiluted drug at 2°8° C (36°46° F).
Adverse Effects (≥1%)Body as a Whole:
Pain, peripheral edema, edema, fever, viral infection, asthenia, arthralgia, acute hypersensitivity reactions with any dose. CNS:
Headache, tremor, dizziness, insomnia
, paresthesias, agitation, depression
Hypertension, chest pain, hypotension, arrhythmias. GI: Constipation
, nausea, diarrhea, abdominal pain, vomiting, dyspepsia, moniliasis, flatulence, GI hemorrhage, melena, esophagitis,
erosive stomatitis. Hematologic:
Anemia, thrombocytopenia, thrombosis, polycythemia. Respiratory:
Dyspnea, URI, cough, rhinitis, pharyngitis, bronchospasm. Skin:
Poor wound healing, acne
Dysuria, UTI, albuminuria, hematuria, oliguria, frequency, renal
tubular necrosis, urinary retention. Other: Cataract
Hyperkalemia, hypokalemia, hyperglycemia, hyperuricemia, hypophosphatemia, hypocalcemia, increased weight, hypercholesterolemia,
36 days. Distribution:
Binds to interleukin-2R-alpha sites on lymphocytes. Half-Life:
7.2 ± 3.2 d in adults, 11.5 ± 6.3 d in children.
Assessment & Drug Effects
- Monitor carefully for and immediately report S&S of opportunistic infection or anaphylactoid reaction (see Appendix F).
Patient & Family Education
- Report any distressing adverse effects.
- Avoid vaccination for 2 wk following last dose of drug.